Published in Br J Clin Pharmacol on October 01, 1985
Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci (1983) 6.89
Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J (1970) 3.80
A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine. Experientia (1969) 2.31
beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol (1976) 2.17
Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol (1971) 1.92
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Effect of route of administration on the relationship between -adrenergic blockade and plasma propranolol level. Clin Pharmacol Ther (1972) 1.48
Spuriously low plasma propranolol concentrations resulting from blood collection methods. Clin Pharmacol Ther (1975) 1.46
High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma. J Chromatogr (1978) 1.30
Measurement of partial agonist activity of pindolol. Clin Pharmacol Ther (1981) 1.13
Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol (1982) 1.08
Pharmacological analysis of beta-adrenoceptor-mediated agonism in the guinea-pig, isolated, right atrium. Br J Pharmacol (1985) 0.98
Duration of action and plasma levels of beta-adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.95
Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia. Eur J Clin Pharmacol (1974) 0.94
Diminishing hypotensive effect of increasing doses of pindolol in DOCA/saline hypertensive rats. Br J Pharmacol (1978) 0.85
Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br J Clin Pharmacol (1982) 0.83
[Clinicopharmacological studies with pindolol following intravenous and oral administration]. Adv Clin Pharmacol (1976) 0.80
Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ (1989) 4.76
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine. Experientia (1969) 2.31
beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol (1976) 2.17
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
A new technique for recording compliance of human hand veins. Br J Clin Pharmacol (1981) 1.80
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
Blood levels of practolol following intravenous administration. Br J Pharmacol (1970) 1.61
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem (1983) 1.38
Isoprenaline antagonism and duration of action in exercise induced tachycardia of three -adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol. Br J Pharmacol (1973) 1.35
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Variability in prescription drug utilization: issues for research. CMAJ (1996) 1.24
Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int J Clin Pharmacol Biopharm (1977) 1.19
Venoconstrictor effect of dihydroergotamine in superficial hand veins. Eur J Clin Pharmacol (1974) 1.15
The influence of beta-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia. Br J Clin Pharmacol (1982) 1.15
Quinidine-rifampin interaction. N Engl J Med (1981) 1.14
Measurement of partial agonist activity of pindolol. Clin Pharmacol Ther (1981) 1.13
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
[Peripheral circulatory effects of ergotamine, dihyroergotamine and 1-methylergotamine on the innevated, perfused hindlimb of the o]. Helv Physiol Pharmacol Acta (1967) 1.11
Phenytoin-theophylline interaction. N Engl J Med (1982) 1.10
Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology (1988) 1.08
Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol (1982) 1.08
Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity. Br J Clin Pharmacol (1985) 1.08
Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol (1982) 1.08
The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram. Postgrad Med J (1970) 1.03
Relationships between heart rate and PR interval during physiological and pharmacological interventions. Br J Clin Pharmacol (1987) 1.03
An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit (1983) 1.03
Grapefruit juice--felodipine interaction in the elderly. Clin Pharmacol Ther (2000) 1.01
Severe coughing during captopril and enalapril therapy. CMAJ (1986) 1.01
Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther (1985) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Tolerance and cardiovascular effects of single dose felodipine/beta-blocker combinations in healthy subjects. J Cardiovasc Pharmacol (1987) 0.97
A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med (1984) 0.97
Duration of action and plasma levels of beta-adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.95
Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol (1984) 0.95
Prolonged action of pindolol. Br Med J (1973) 0.94
A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke (1985) 0.93
Increased venous alpha-adrenoceptor responsiveness in patients with reflex sympathetic dystrophy. Ann Intern Med (1993) 0.93
Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol (1987) 0.92
Intravenous diazepam in minor oral surgery. Further studies. Br Dent J (1970) 0.91
Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation (1982) 0.91
Use of a linear variable differential transformer to measure compliance of human hand veins in situ [proceedings]. Br J Clin Pharmacol (1979) 0.91
Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther (1986) 0.91
Clinical pharmacology of pindolol. Am Heart J (1982) 0.91
Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations. J Pharm Sci (1988) 0.89
The influence of age on dorsal hand vein responsiveness to norepinephrine. Clin Pharmacol Ther (1986) 0.87
The effect of graded doses of practolol on the tachycardia induced by isoprenaline, Valsalva's manoeuvre and exercise. Br J Pharmacol (1970) 0.86
Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol (1990) 0.86
Simplified liquid-chromatographic assay of amiodarone and desethylamiodarone after solid-phase extraction. Clin Chem (1986) 0.86
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. Br J Clin Pharmacol (1993) 0.85
A method for the fluorimetric determination of thioridazine (Mellaril) or mesoridazine (Lidanil) in plasma. Experientia (1969) 0.84
Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man. Eur J Clin Pharmacol (1984) 0.84
Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol (1989) 0.83
Cardiac effects of adrenaline and felypressin as vasoconstrictors in local anaesthesia for oral surgery under diazepam sedation. Br J Anaesth (1970) 0.83
Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. Br J Clin Pharmacol (1986) 0.83
Familial studies of heritability of alpha1-adrenergic receptor responsiveness in superficial veins. Clin Pharmacol Ther (1997) 0.82
Investigations with beta-adrenoceptor blocking drugs in healthy volunteers. Acta Med Scand Suppl (1977) 0.82
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
A new technique for recording compliance of human hand veins. 1981. Br J Clin Pharmacol (2004) 0.82
Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Br J Pharmacol (1969) 0.82
Genetic aspects of variability in superficial vein responsiveness to norepinephrine. Clin Pharmacol Ther (1991) 0.82
Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. Eur J Clin Pharmacol (1991) 0.81
Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers. Eur J Clin Pharmacol (1978) 0.81
Ineffectiveness of beta-adrenergic blockers on ventilatory response to carbon dioxide. Clin Pharmacol Ther (1982) 0.81
Methods for studying drug effects on superficial human veins. Methods Find Exp Clin Pharmacol (1985) 0.81
[Clinicopharmacological studies with pindolol following intravenous and oral administration]. Adv Clin Pharmacol (1976) 0.80
A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet. Eur J Clin Pharmacol (1981) 0.79
Studies on the venoconstrictor effect of ergot compounds in man. Triangle (1975) 0.78
Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol (1986) 0.78
Influence of ergot compounds on compliance of superficial hand veins in man. Postgrad Med J (1976) 0.78
Activity and duration of action of pindolol and alprenolol compared in healthy volunteers. Eur J Clin Pharmacol (1978) 0.77
Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension (1994) 0.77
A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. Stroke (1989) 0.77
Experiments with pindolol (Visken) in healthy volunteers. Med J Aust (1977) 0.76
Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade. Eur J Clin Pharmacol (1984) 0.76
Quinidine interaction with nifedipine and felodipine: pharmacokinetic and pharmacodynamic evaluation. Clin Pharmacol Ther (1993) 0.76
Plasma and tissue digoxin concentrations in patients undergoing cardiopulmonary bypass. Br Heart J (1975) 0.76
Direct effects of vasoactive substances on superficial human veins in vivo. Int Angiol (1986) 0.76
The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig. Br J Pharmacol (1991) 0.75
Vasovagal faint in the supine position. Br Med J (1970) 0.75
[Effect of ergot alkaloids on venous tonus determined in superficial hand veins in situ]. Cardiology (1976) 0.75
Persistent tardive dyskinesia. Br Med J (1971) 0.75
Influence of pizotifen and ergotamine on the venoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man. Eur J Clin Pharmacol (1983) 0.75
The acute exercise test for the preliminary evaluation of beta-receptor blocking drugs in angina pectoris. Br J Pharmacol (1969) 0.75
The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function. Br J Clin Pharmacol (1990) 0.75
Agonists and antagonists of 5-hydroxytryptamine on venomotor receptors. Adv Neurol (1982) 0.75
Clinical pharmacology of beta-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol. J Cardiovasc Pharmacol (1983) 0.75
Comparison of the electrophysiologic effects of intravenous and oral verapamil in patients with paroxysmal supraventricular tachycardia. Am J Cardiol (1982) 0.75
Duration of drug action. Am Fam Physician (1980) 0.75
Observations on three dosage forms of pindolol. Am Heart J (1982) 0.75
Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker. Clin Pharmacol Ther (1979) 0.75